BERKELEY HEIGHTS, NJ - December 30, 2005-
Genta Incorporated (NASDAQ: GNTA) announced that the Company will
hold a conference call for investors to provide an update related
to near-term regulatory activities for its lead anticancer compound
Genasense® (oblimersen sodium) injection, and other upcoming
Company milestones on Wednesday, January 4, 2006 at 9:00 AM ET.
Raymond P. Warrell, Jr., M.D., Chairman and Chief Executive Officer
will host the conference call.
The conference call can be accessed live as follows:
US/Canada Dial-in: (877) 634-8606 Passcode: Genta Incorporated
International Dial-In: (706) 679-3140 Passcode: Genta Incorporated
Live audio webcast:
http://www.genta.com/genta/InvestorRelation/events.html
Audio replay will be available approximately two hours after the
completion of the call and will be archived for 30 days.
About Genta
Genta Incorporated is a biopharmaceutical company with a
diversified product portfolio that is focused on delivering
innovative products for the treatment of patients with cancer. The
Company's research platform is anchored by two major programs that
center on oligonucleotides (RNA- and DNA-based medicines) and small
molecules. Genasense® (oblimersen sodium) Injection, the Company's
lead compound from its oligonucleotide program, is currently
undergoing late-stage, Phase 3 clinical testing. The Company has
filed a new drug application (NDA) to the U.S. FDA for the use of
Genasense in combination with chemotherapy for the treatment of
relapsed or refractory CLL. In addition, the Company has also
indicated it s intention to submit a Marketing Authorization
Application (MAA) to the European Medicines Agency (EMEA) for the
use of Genasense plus dacarbazine in patients with advanced
melanoma before the end of 2005. The leading drug in Genta's small
molecule progr am is Ganite® (gallium nitrate injection), which the
Company is exclusively marketing in the U.S. for treatment of
patients with cancer related hypercalcemia that is resistant to
hydration. For more information about Genta, please visit our
website at:
http://www.genta.com/
.
Genta Forward Looking Statement
This press release contains forward-looking statements with
respect to business conducted by Genta Incorporated. By their
nature, forward-looking statements and forecasts involve risks
and uncertainties because they relate to events and depend on
circumstances that will occur in the future. There are a number
of factors that could cause actual results and developments to
differ materially. For a discussion of those risks and
uncertainties, please see the Company's Annual Report/Form 10-K
for 2004.
SOURCE: Genta Incorporated
